

Resource Summary Report

Generated by SPARC SAWG on Aug 9, 2026

PE/Cyanine7 anti-human CD3

RRID:AB_2561452

Type: Antibody

Proper Citation

BioLegend Cat# 317334, RRID:AB_2561452

Antibody Information

URL: http://antibodyregistry.org/AB_2561452

Proper Citation: BioLegend Cat# 317334, RRID:AB_2561452

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_2561452

Vendor: BioLegend

Catalog Number: 317334

Alternative Catalog Numbers: 317333

Record Creation Time: 20250820T001522+0000

Record Last Update: 20250820T074730+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human CD3.

No alerts have been found for PE/Cyanine7 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Li J, et al. (2026) Multimodal clocks of human aging. Cell, 189(14), 4489.

Zhao Z, et al. (2025) Sickle cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity. Immunity, 58(6), 1484.

Blass E, et al. (2025) A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma. Cell.

Geng L, et al. (2025) Systematic profiling reveals betaine as an exercise mimetic for geroprotection. Cell.

Maulana TI, et al. (2024) Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells. Cell stem cell, 31(7), 989.

Quiros-Fernandez I, et al. (2024) Dual T cell receptor/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells. Journal of medical virology, 96(5), e29630.

Ni L, et al. (2020) Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity, 52(6), 971.